Report post
Aarti Drugs Ltd faces challenges in its oncology formulations biz, with limited revenue expectations in FY25. Sandeep Jain remains optimistic, citing strong domestic market volumes and healthy EBITDA margins. Investors should stay tuned for updates on the company's performance and strategy, while considering other stock market opportunities.

The World's Leading Crypto Trading Platform

Get my welcome gifts